NASDAQ$CRBP
Corbus Pharmaceuticals Holding · Q1 2023 earnings
Q1 2023 earnings · · Investor relations
Briefing
Reported first quarter 2023 financial results and provided corporate update.
Corbus Pharmaceuticals reported a net loss of $17.7 million for the first quarter of 2023. The company's operating expenses increased due to the upfront payment for the CSPC License Agreement and a development milestone under the USCF License Agreement. As of March 31, 2023, the company's cash and investments are expected to fund operations through the second quarter of 2024.
- Expanded precision oncology pipeline with in-licensing of CRB-701, a clinical-stage Nectin-4 antibody drug conjugate (ADC) from CSPC Pharmaceutical Group.
- CRB-701 Phase 1 dose escalation study ongoing in patients with advanced solid tumors in China.
- Presented latest CRB-601 anti-αvβ8 mAb pre-clinical data at American Association of Cancer Research (AACR) 2023 annual meeting with IND submission on track for the second half of 2023.
- Expanded Board of Directors with appointment of Yong Ben, MD.
Headline financials
Revenue & EPS history
Corbus Pharmaceuticals · Revenue · Quarterly
$0
Forward guidance
Corbus Pharmaceuticals expects that its cash and investments on hand as of March 31, 2023, will fund operations through the second quarter of 2024.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q1 2023
-1.6%
Avg return
Earnings day
-0.2%
Avg return
5 days after
+8.6%
Avg return
30 days after
30%
14 / 46 earnings
Positive
+23.0%
Q4 2023
Best reaction
-24.2%
Q3 2023
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +4.0% | +0.1% | -29.3% | |
| Q4 2025 | +18.6% | +17.5% | +22.8% | |
| Q3 2025 | +6.5% | +8.0% | -6.9% | |
| Q1 2025 | -16.3% | -13.1% | +18.6% | |
| Q4 2024 | -9.1% | -17.4% | -13.4% | |
| Q3 2024 | -0.7% | -5.1% | -19.3% | |
| Q2 2024 | -12.2% | +2.8% | -7.7% | |
| Q1 2024 | +9.2% | +10.7% | +20.0% | |
| Q4 2023 | +23.0% | +14.1% | +4.5% | |
| Q3 2023 | -24.2% | -35.5% | +7.1% | |
| Q2 2023 | -4.7% | +3.9% | +9.5% | |
| Q1 2023 | -8.1% | -2.9% | -8.0% | |
| Q4 2022 | -11.6% | -24.9% | +171.9% | |
| Q3 2022 | -3.8% | +1.5% | -0.8% | |
| Q2 2022 | -4.5% | -3.7% | -25.5% | |
| Q1 2022 | -10.6% | -19.2% | +12.5% | |
| Q4 2021 | +15.4% | +25.5% | +32.7% | |
| Q3 2021 | +5.7% | -3.8% | -28.8% | |
| Q2 2021 | -6.8% | -7.5% | -10.5% | |
| Q1 2021 | +12.1% | +9.4% | +46.3% | |
| Q4 2020 | -6.4% | +0.9% | -25.3% | |
| Q3 2020 | +0.0% | +4.9% | +8.2% | |
| Q2 2020 | -7.6% | -2.7% | +29.4% | |
| Q1 2020 | +3.3% | +4.3% | +11.0% | |
| Q4 2019 | -1.2% | +2.2% | +39.6% | |
| Q3 2019 | -6.4% | -11.0% | +4.7% | |
| Q2 2019 | +3.2% | +7.0% | -4.4% | |
| Q1 2019 | -0.8% | -4.9% | -9.9% | |
| Q4 2018 | +8.1% | +11.1% | +17.1% | |
| Q3 2018 | -13.3% | -16.5% | -9.4% | |
| Q2 2018 | +0.0% | +2.6% | +12.5% | |
| Q1 2018 | -14.5% | -1.6% | -10.2% | |
| Q4 2017 | -4.9% | +0.0% | -12.7% | |
| Q3 2017 | +2.9% | +0.0% | +10.2% | |
| Q2 2017 | -4.1% | -0.8% | +10.7% | |
| Q1 2017 | -4.0% | +1.6% | +2.4% | |
| Q4 2016 | +1.6% | +4.4% | -20.9% | |
| Q3 2016 | -9.3% | +26.4% | +20.9% | |
| Q2 2016 | -1.0% | +5.5% | +67.2% | |
| Q1 2016 | -2.5% | — | — | |
| Q4 2015 | -3.8% | — | — | |
| Q3 2015 | -1.8% | — | — | |
| Q2 2015 | -6.1% | — | — | |
| Q1 2015 | -2.5% | — | — | |
| Q4 2014 | -0.5% | — | — | |
| Q3 2014 | +16.7% | — | — | |
| Q2 2014 | — | — | — | |
| Q1 2014 | — | — | — | |
| Q4 2013 | — | — | — | |
| Q3 2013 | — | — | — | |
| Q2 2013 | — | — | — | |
| Q1 2013 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro